Podcast
Antisense Oligonucleotides (ASOs)
Antisense oligonucleotides (ASOs) are being developed as treatments for rare genetic disorders such as SCN2A. What are they and how do they work?
© All rights reserved. SCN2A Australia | Privacy Policy
epilepsy
Categories
Webinar
Developing Treatment for SCN2A
Prof Steven Petrou and Dr Kiran Reddy discuss the RC-222 program developing an ASO treatment for gain-of-function SCN2A epilepsies.
Webinar – Working towards SCN2A treatment
Speakers: Prof. Steven Petrou, Director of the Florey and RogCon, Chief Scientific Officer, and Dr. Kiran Reddy, CEO of Praxis Precision Medicines. At the 2018
Podcast
Demystifying Genetic Testing
Genetic testing is complex. To decipher some of the terminolgy and help explain the process we talked to Dr Emma Palmer, Clinical Geneticist.
Podcast
Sleep in Children with Developmental Disabilities
Children with developmental disabilities can have touble with sleep. Assoc Prof Margot Davey discusses what can be done to improve sleep in these children.
Podcast
Citizens United for Research in Epilepsy (CURE)
CURE Epilepsy has raised more than $60 million to fund epilepsy research. We talk with Dr Laura Lubbers about the work CURE Epilepsy is doing.
Podcast
Achieve More by Working Together
Working collaboratively has been one of the hallmarks of Prof Daniel Lowenstein’s career and has led to breakthrough research.
Podcast
Developing Treatments for SCN2A
We talk with Dr Kiran Reddy about the plans for the RC-222 treatment program with the goal of developing a treatment for SCN2A gain-of-function epilepsies.
Podcast
Developing treatments as a parent
When Alex Nemiroff’s son was born, he was determined to work towards finding treatments for SCN2A, and is now CEO of RogCon with a treatment in development.
Podcast
Natural History Study for SCN2A
Natural History Studies (NHS) are important in planning trials of treatment. We talk with Dr Katherine Howell, principal investigator of the SCN2A NHS.